Dr. Robson on Differences Between Biosimilars and Biologics in Oncology

Video

In Partnership With:

Mark E. Robson, MD, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

Educational efforts regarding the development and approval process for biosimilars could help reduce the skepticism that is associated with these agents, says Robson.

Regulatory pathway differences between biosimilars and originator compounds are often misunderstood. Explanation of the biosimilar approval process could help clarify these differences and shed light on the current criteria that are used to demonstrate similarity between these agents, concludes Robson.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD